FOLFOX-4

DRUG5 trials

Sponsors

Amgen, Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD), Institut du Cancer de Montpellier - Val d'Aurelle, Hoffmann-La Roche, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente

Conditions

ChemotherapyColon CancerColorectal CancerLiver MetastasesMetastatic Colorectal CancerRectal Cancer

Phase 1

Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal Cancer

CompletedNCT00101894

AmgenColon Cancer, Rectal Cancer

Start: 2004-12-31End: 2011-12-31Updated: 2012-09-17

Phase 2

Safety and Efficacy Study of Combination Therapy With Cetuximab and FOLFOX4 in Patients With Colorectal Cancer

CompletedNCT00202787

Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Colorectal Cancer

Start: 2005-02-28End: 2009-02-28Updated: 2013-02-20

Intensified Chemotherapy in CRC After Resection of Liver Metastases

CompletedNCT00208260

Institut du Cancer de Montpellier - Val d'AurelleChemotherapy, Colorectal Cancer, Liver Metastases

Start: 2004-04-01End: 2007-08-01Updated: 2026-02-05

Phase 3

A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.

CompletedNCT00349336

Hoffmann-La RocheColorectal Cancer

Start: 2006-08-31End: 2008-11-30Updated: 2012-09-18

Trial Comparing Two Two Sequences of Therapy in Colorectal Metastatic Patients

CompletedNCT01030042

Gruppo Italiano per lo studio dei Carcinomi dell'Apparato DigerenteMetastatic Colorectal Cancer

Start: 2009-09-30End: 2015-06-30Updated: 2015-07-15

Related Papers

Efficacy of cetuximab immediately after bevacizumab: A phase III multicenter trial comparing two different sequences of cetuximab and FOLFOX in K-Ras WT metastatic colorectal cancer patients refractory FOLFIRI/bevacizumab.

Journal of Clinical Oncology2016-02-011 citations

A phase III multicenter trial comparing two different sequences of second/third line therapy (irinotecan/cetuximab followed by FOLFOX-4 vs. FOLFOX-4 followed by irinotecan/cetuximab in K-RAS wt metastatic colorectal cancer (mCC) patients refractory to FOLFIRI/Bevacizumab.

Journal of Clinical Oncology2015-05-203 citations